US › Healthcare

Cellectis SA (CLLS)

US · Healthcare · Biotechnology

$1.04-5.88%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$5.2M

Revenue YoY

-68.8%

Net profit

$-21.8M

EPS

$-0.22

EPS estimate

$-0.25

Net margin

-417.3%

EPS came in at -0.22 against a street estimate of -0.25 — a beat of 12.0%.

Key statistics

Market cap

$110.8M

Forward P/E

0.0

P/B

3.85

Book value

$0.56

EPS (TTM)

$-0.64

52-week high

$5.48

52-week low

$1.09

50-day MA

$2.39

200-day MA

$3.30

Beta

2.91

Analyst view

Analysts rate Cellectis SA a buy (2 buy, 2 hold, 1 sell out of 5) with an average price target of $4.83.

Shareholding

Institutions

13.43%

Largest institutional holders

Fund	Stake
B Group, Inc	3.26%
Long Focus Capital Management, LLC	2.72%
UBS Asset Mgmt Americas Inc	2.63%
Delaware Management Holdings Inc	0.23%
BlackRock Inc	0.22%
Morgan Stanley - Brokerage Accounts	0.08%
LPL Financial Corp	0.08%
Susquehanna International Group, LLP	0.05%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Cellectis SA — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.